Phase I/II Study of Oral ONC201 in Patients with Relapsed or Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes
The goal of Phase I of this clinical research study is to find the highest tolerable dose of ONC201 that can be given to patients with relapsed or refractory AML, ALL, or MDS. The goal of Phase II of this study is to learn if the dose of ONC201 found in Phase I can help to control the disease. The safety of the study drug will be studied in both phases of this study. This is the first study using ONC201 in humans.
Disease Group: Leukemia
Treatment Agent: Cytarabine, ONC201
Treatment Location: Only at MD Anderson
Sponsor: Oncoceutics, Inc.
IRB Review and Approval Date: 11/03/2015
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
Phase I/Phase II
For general questions about clinical trials: